Aurora Cannabis Inc. announced the expansion of its popular IndiMed brand in Australia with the launch of IndiMed TEMPO 22, available through its subsidiary, MedReleaf Australia. This new offering introduces a 22% THC potency, providing a greater range of treatment options for prescribers.
IndiMed remains one of the most prescribed medical cannabis brands for patients in Australia. The addition of two new cultivars under the TEMPO 22 line reinforces Aurora's commitment to meeting diversified patient needs with accessible, high-quality medical cannabis options.
This expansion highlights Aurora's continued focus on international growth and dedication to providing innovative products. MedReleaf Australia maintains its commitment to quality and adherence to TGA-GMP standards for all its offerings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.